xmab22841 Report issue

Biologics mAb Multi-specific Experimental

Active Ingredient History

NOW
  • Now

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Yes
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Organizations (2)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (23)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (23)


 

Carcinoma, Hepatocellular (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Carcinoma, Ovarian Epithelial (Phase 1)

Carcinoma, Renal Cell (Phase 1)

Carcinoma, Transitional Cell (Phase 1)

Cholangiocarcinoma (Phase 1)

Colorectal Neoplasms (Phase 1)

Endometrial Neoplasms (Phase 1)

Esophageal Neoplasms (Phase 1)

Fallopian Tube Neoplasms (Phase 1)

Hamartoma (Phase 1)

Melanoma (Phase 1)

Nasopharyngeal Carcinoma (Phase 1)

Neoplasms (Phase 1)

Pancreatic Neoplasms (Phase 1)

Penile Neoplasms (Phase 1)

Prostatic Neoplasms (Phase 1)

Rectal Neoplasms (Phase 1)

Small Cell Lung Carcinoma (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Triple Negative Breast Neoplasms (Phase 1)

Uterine Cervical Neoplasms (Phase 1)

Vulvar Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue